Tokyo, Jan. 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060523) titled 'Disease burden of COVID-19 under post-pandemic in Japanese population' on Jan. 31.
Study Type:
Observational
Primary Sponsor:
Institute - Takeda Pharmaceutical Company Limited
Condition:
Condition - COVID-19 and seasonal influenza
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to quantitatively examine the disease burden of COVID-19 after its transition to a Category 5 infectious disease by using an insurance claims database and comparing it with seasonal influenza.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-uppe...